ASCO: Time Management for the Busy Oncologist

Video

Tim Moynihan of the Mayo Clinic in Minnesota discusses topics from the session he chaired at ASCO, "Effective Time Management for the Busy Oncologist," including why EHRs may not actually save physicians time; how to manage your email load; and tips for avoiding burnout, which he cites as a danger in such a physically and emotionally taxing profession.

Tim Moynihan of the Mayo Clinic in Minnesota discusses topics from the session he chaired at ASCO, "Effective Time Management for the Busy Oncologist," including why EHRs may not actually save physicians time; how to manage your email load; and tips for avoiding burnout, which he cites as a danger in such a physically and emotionally taxing profession.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content